Expert recommendations for biological treatment in patients with psoriasis

Podoswa-Ozerkovsky, Nancy; Amaya-Guerra, Mario; Barba‐Gómez, José Fernando; Estrada-Aguilar, Lorena; Gómez‐Flores, Minerva; Lopeztello-Santillán, Adriana L.; Maldonado-García, César; Rivera-Gómez, Mónica I; Villanueva-Quintero, Delfina Guadalupe; León-Dorantes, Gladys

doi:10.24875/gmm.m20000441

Cited by 3 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Além dele, o etanercept mesmo sendo um anticorpo monoclonal, demonstrou transmissibilidade placentária mínima. Assim, se necessário o uso de biológicos durante a gestação, a primeira escolha seria o certolizumab pegol, seguido do etanercept (PODOSWA-OZERKOVSKY et al, 2020).…”

Section: Discussionunclassified

Análise Do Padrão De Resistência Antimicrobiana E Dos Fatores De Risco Das Infecções Estafilocócicas No Período Neonatal Em Um Hospital De Referência Em Pediatria: Uma Coorte Retrospectiva

Gonçalves,

Brandelero,

Frohlich

et al. 2023

Medicina: Competências Técnica, Cientifica E Ética Na Área Da Saúde 2

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

Análise Do Padrão De Resistência Antimicrobiana E Dos Fatores De Risco Das Infecções Estafilocócicas No Período Neonatal Em Um Hospital De Referência Em Pediatria: Uma Coorte Retrospectiva

Gonçalves,

Brandelero,

Frohlich

et al. 2023

Medicina: Competências Técnica, Cientifica E Ética Na Área Da Saúde 2

View full text Add to dashboard Cite

show abstract

“…For obese patients who do not respond to standard dosage, increasing the dosage or shortening the dosing interval may be considered. 5 Therefore, infliximab can be used to treat psoriasis with comorbid obesity. The direct effects of IL-17 inhibitors on obesity have not been clearly documented.…”

Section: Obesitymentioning

confidence: 99%

Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A Literature Review

Wang,

Zhang,

et al. 2023

CCID

View full text Add to dashboard Cite

This literature review systematically searched relevant literature from the past 10 years using various medical databases, including PubMed, Medline, Cochrane, China National Knowledge Infrastructure (CNKI), Wanfang, and Weipu. As a chronic inflammatory disease, psoriasis is associated with various cells and cytokines of the body's immune system, making them more susceptible to various systemic comorbidities than the general population. At a time when conventional regimens are ineffective and there is a lack of personalized treatment options for such comorbidities, the development of biologics has revolutionized the treatment of psoriasis comorbidities, and a number of biologic combination therapies have been incorporated into first-line treatments in many countries. The focus of this review was to investigate the relationship between psoriasis and comorbidities, such as metabolic syndrome, psoriatic arthritis, cardiovascular diseases, mental disorders, infectious diseases, digestive system diseases, and renal diseases. Furthermore, the study explored the significance of biologic therapies in the management of these comorbidities. Also this paper suggests current conditions and precautions for the use of biologic therapies to minimize the occurrence of adverse effects. This review was performed to provide guidance for clinical drug selection in patients with psoriasis and comorbidities, as well as serve as a reference for the development and application of biologic therapies.

show abstract

“…As a chronic, inflammatory, immune-mediated systemic disease induced by genetic and environmental factors, psoriasis has a prevalence of about 1-4% of the world's population. 1 Lifelong treatment is often required, and topical therapy plays an important role as first-line therapy for patients with mild to moderate psoriasis, especially for those with localized psoriasis vulgaris.…”

Section: Introductionmentioning

confidence: 99%

Four cases of localized plaque psoriasis successfully treated by intense pulsed light: A case series

Cheng

Gao

et al. 2023

Eur J Inflamm

View full text Add to dashboard Cite

Four patients with localized plaque psoriasis had used various systemic drugs along with topical cream. However, their skin lesions recurred, and the disease was refractory. After 2 weeks of discontinuation of oral and external medication, they were given three consecutive irradiation treatments with intense pulsed light once every 2 weeks for a 6-week period. After treating for 6 weeks, the erythema colors of the patients were evidently darkened, the scales were evidently reduced, and the skin lesions were significantly thinner or even flattened. The treatment was satisfactory, without occurrence of severe adverse reactions.

show abstract

Expert recommendations for biological treatment in patients with psoriasis

Cited by 3 publications

References 46 publications

Análise Do Padrão De Resistência Antimicrobiana E Dos Fatores De Risco Das Infecções Estafilocócicas No Período Neonatal Em Um Hospital De Referência Em Pediatria: Uma Coorte Retrospectiva

Análise Do Padrão De Resistência Antimicrobiana E Dos Fatores De Risco Das Infecções Estafilocócicas No Período Neonatal Em Um Hospital De Referência Em Pediatria: Uma Coorte Retrospectiva

Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A Literature Review

Four cases of localized plaque psoriasis successfully treated by intense pulsed light: A case series

Contact Info

Product

Resources

About